Increased cytoplasmic mislocalization of TAR DNA binding protein 43 (TDP-43) in circulating lymphomonocytes of ALS patients recapitulates the major dysfunction featuring motor neurons in the disease. by De Marco, Giovanni et al.
14 December 2021
AperTO - Archivio Istituzionale Open Access dell'Università di Torino
Original Citation:
Increased cytoplasmic mislocalization of TAR DNA binding protein 43 (TDP-43) in circulating lymphomonocytes of




(Article begins on next page)
Anyone can freely access the full text of works made available as "Open Access". Works made available under a
Creative Commons license can be used according to the terms and conditions of said license. Use of all other works
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
Availability:
IPoletti A, Cattaneo E, Taroni F, Milano, Incentives e Congressi,
This is a pre print version of the following article:
This version is available http://hdl.handle.net/2318/149151 since 2016-11-29T15:28:44Z
Monocytes of patients with amyotrophic lateral
sclerosis linked to gene mutations display altered
TDP-43 subcellular distribution
G. De Marco*,1, A. Lomartire*,1, A. Calvo*,†, A. Risso‡, E. De Luca‡, M. Mostert§, J. Mandrioli¶,
C. Caponnetto**, G. Borghero††, U. Manera*,†, A. Canosa†,**, C. Moglia*,†, G. Restagno‡‡,
N. Fini¶, C. Tarella§§, M. T. Giordana*, M. T. Rinaudo¶¶ and A. Chio*,†
*‘Rita Levi Montalcini’ Department of Neuroscience, University of Turin, †ALS Center, University of Turin and AOU
Citta della Salute e della Scienza, ‡Molecular Biotechnology Center, §Department of Public Health and Pediatric
Sciences, University of Turin, Turin, ¶Department of Neuroscience, Sant’Agostino Estense Hospital, University of
Modena, Modena, **Department of Neurosciences, Ophthalmology, Genetics, Rehabilitation and Child Health, IRCCS
AOU San Martino IST, University of Genoa, Genoa, ††Department of Neurology, AOU and University of Cagliari,
Cagliari, ‡‡Molecular Genetics Unit, Department of Clinical Pathology, AOU Citta della Salute e della Scienza,
University of Turin, Turin, §§Clinical Hemato-Oncology, European Institute of Oncology (IEO), Milan and
¶¶Department of Oncology, University of Turin, Turin, Italy
G. De Marco, A. Lomartire, A. Calvo, A. Risso, E. De Luca, M. Mostert, J. Mandrioli, C. Caponnetto,
G. Borghero, U. Manera, A. Canosa, C. Moglia, G. Restagno, N. Fini, C. Tarella, M. T. Giordana,
M. T. Rinaudo, A. Chio (2016) Neuropathology and Applied Neurobiology
Monocytes of patients with amyotrophic lateral sclerosis linked to gene mutations display altered
TDP-43 subcellular distribution
Aims: Cytoplasmic accumulation of the nuclear protein
transactive response DNA-binding protein 43 (TDP-43)
is an early determinant of motor neuron degeneration
in most amyotrophic lateral sclerosis (ALS) cases. We
previously disclosed this accumulation in circulating
lymphomonocytes (CLM) of ALS patients with mutant
TARDBP, the TDP-43-coding gene, as well as of a
healthy individual carrying the parental TARDBP
mutation. Here, we investigate TDP-43 subcellular
localization in CLM and in the constituent cells, lym-
phocytes and monocytes, of patients with various ALS-
linked mutant genes. Methods: TDP-43 subcellular
localization was analysed with western immunoblotting
and immunocytofluorescence in CLM of healthy con-
trols (n = 10), patients with mutant TARDBP (n = 4, 1
homozygous), valosin-containing protein (VCP; n = 2),
fused in sarcoma/translocated in liposarcoma (FUS;
n = 2), Cu/Zn superoxide dismutase 1 (SOD1; n = 6),
chromosome 9 open reading frame 72 (C9ORF72; n = 4),
without mutations (n = 5) and neurologically unaf-
fected subjects with mutant TARDBP (n = 2). Results:
TDP-43 cytoplasmic accumulation was found
(P < 0.05 vs. controls) in CLM of patients with mutant
TARDBP or VCP, but not FUS, in line with TDP-43
subcellular localization described for motor neurons of
corresponding groups. Accumulation also characterized
CLM of the healthy individuals with mutant TARDBP
and of some patients with mutant SOD1 or C9ORF72.
In 5 patients, belonging to categories described to carry
TDP-43 mislocalization in motor neurons (3 C9ORF72,
1 TARDBP and 1 without mutations), TDP-43 cytoplas-
mic accumulation was not detected in CLM or in lym-
phocytes but was in monocytes. Conclusions: In ALS
forms characterized by TDP-43 mislocalization in motor
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neurons, monocytes display this alteration, even when
not manifest in CLM. Monocytes may be used to
support diagnosis, as well as to identify subjects at risk,
of ALS and to develop/monitor targeted treatments.
Keywords: amyotrophic lateral sclerosis, gene mutations, monocytes, transactive response DNA-binding protein 43
subcellular localization
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal adult
onset neurodegenerative disorder characterized by
selective loss of motor neurons in the brain and spinal
cord and is presently incurable [1,2]. In about 5–10%
of cases, the disease has a family history [familial amy-
otrophic lateral sclerosis (fALS)], whereas in the major-
ity of cases a familial background is not documented
[sporadic amyotrophic lateral sclerosis (sALS)]. Muta-
tions of more than thirty genes ([3] http://al-
sod.iop.kcl.ac.uk), usually inherited in an autosomal
dominant pattern, have been found in about two-thirds
of fALS and in some sALS cases [2]. Genetic and non-
genetic forms are clinically indistinguishable [4,5].
ALS, besides being a multifunction and multifactorial
disease, is a multisystem disease affecting not only
motor neurons, but also other cells and tissues, such as
glia as well as cells of the immune system and skeletal
muscle [6–15].
A typical trait of ALS is the presence in the cyto-
plasm of motor neurons and glial cells of proteina-
ceous ubiquitin-immunoreactive aggregates, appearing
as round or skein-like inclusions [16–18]. However,
these inclusions are not specific for ALS, since they
characterise the central nervous system (CNS) in
other neurodegenerative diseases [19]. Transactive
response DNA-binding protein 43 (TDP-43) is a ubiq-
uitously expressed transcription factor localized mainly
in the nucleus and minimally in the cytoplasm as it
continuously shuttles between the two compartments
[20,21]. In 2006, TDP-43 was discovered to be the
main component of the cytoplasmic inclusions charac-
terizing motor neurons of post mortem sALS cases
[22–24], a feature frequently associated with its
depletion in the nucleus [25,26]. However, our inves-
tigations revealed that TDP-43 may accumulate in
the cytoplasm of motor neurons also if not seques-
tered inside inclusions [27]. This alteration is consid-
ered an early event in motor neuron degeneration
[4,27–29]. The involvement of TDP-43 in the
pathogenesis of ALS has been strengthened by the
discovery of several mutations in the TDP-43 coding
gene, TARDBP, in some fALS and sALS cases [2].
These mutations predispose nuclear TDP-43 to redis-
tribute to the cytoplasm and to form pathological
aggregates [4,28,30–33].
Clearly, it is not possible to perform evaluations of
TDP-43 subcellular distribution in the CNS ante mor-
tem. Since TDP-43 is ubiquitously distributed, in a
previous study [34] we investigated whether in ALS
patients TDP-43 dysfunctions characterise cells out-
side the CNS. Our attention focused on circulating
lymphomonocytes (CLM) since these cells are avail-
able on demand and without invasive procedures.
We showed that TDP-43 cytoplasmic accumulation,
along with nuclear decrement, was also a feature of
CLM of ALS patients with mutant TARDBP and of
about 50% of those without documented gene muta-
tions. Of note, the same alteration was also revealed
in CLM of a healthy young individual carrying the
same TARDBP mutation of the parent affected by
ALS.
Here, we explore whether, in CLM of ALS patients
with other disease-linked mutant genes, TDP-43 subcel-
lular localization reflects that described in motor neu-
rons of corresponding cases. The mutant genes
examined include valosin-containing protein (VCP), fused
in sarcoma/translocated in liposarcoma (FUS), Cu/Zn
superoxide dismutase 1 (SOD1) and chromosome 9 open
reading frame 72 (C9ORF72). These genes, together
with TARDBP, account for the majority of the ALS
genetic forms [2]; furthermore, some of these mutations
are associated with alterations of TDP-43 in motor
neurons, whereas others are not [4,35–37]. We also
examined the TDP-43 profile separately in lymphocytes
and monocytes, the CLM constituent cells. Thus,
besides the subcellular fractionation/sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE)/western immunoblot (WB) approach previously
applied [34], here we used an immunocytofluorescence
(IF) assay, since the latter allows discrimination within
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the CLM population between lymphocytes and mono-
cytes.
Additionally, we had the opportunity to evaluate the
TDP-43 profile in CLM of three individuals belonging to
a family characterized by an interesting pedigree: one
member was homozygous for the TARDBP mutation
and was affected by a syndrome including ALS,
whereas the other two were heterozygous for the muta-
tion and were neurologically unaffected [38].
Materials and methods
Subjects
The demographic data of neurologically unaffected sub-
jects (controls) recruited in this study are reported in
Table 1. The demographic and clinical characteristics
of the ALS patients considered in this study are sum-
marized in Table 2. Since the previously examined con-
trols, as well as patients with mutant TARDBP and
patients without gene mutations [34] could no longer
be recruited for IF assay, 10 new controls, as well as 3
new patients with mutant TARDBP and 5 new ALS
patients without documented gene mutations were
recruited. Therefore, the case series includes 10 con-
trols, 6 individuals with mutant TARDBP (including 4
patients, 1 of whom was homozygous for the mutation,
and 2 neurologically unaffected subjects), 2 patients
with mutant VCP, 2 patients with mutant FUS, 6
patients with mutant SOD1, 4 patients with mutant
C9ORF72, 5 patients without documented gene muta-
tions and 1 patient with fALS and unknown gene
mutation. Hereafter, individuals are defined as
TARDBP+, VCP+, FUS+, SOD1+ and C9ORF72+
according to the carried gene mutation.
The study design was approved by the institutional
ethics committee. Patients and controls signed written
informed consent.
Reagents
ProteoJet Cytoplasmic and Nuclear Protein Extraction
kit (K0311) and protein molecular markers (SM0671)
were from Fermentas (Milan, Italy). Lymphoprep
(1114545) was from AXIS-SHIELD (Oslo, Norway).
The RC DC protein content assay kit was from Bio Rad
(Milan, Italy). MACS Cell separation kit (130-050-
201) was from Miltenyi Biotec (Bologna, Italy). TDP-43
monoclonal antibody, clone 2E2-D3 (H00023435-
M01), directed to the epitope 205-222 of the human
protein [39] was from Abnova Corporation (Taipei, Tai-
wan). Lamin B1 monoclonal antibody (33-2000) was
from Zymed Laboratories (San Francisco, CA, USA),
while b-tubulin polyclonal antibody (sc-9104), CD45
monoclonal antibody (sc-53666) and secondary anti-
bodies conjugated to horseradish peroxidase (HRP)
were from Santa Cruz Biotechnology (Heidelberg,
Germany). Ubiquitin monoclonal antibody (MAB1510),
secondary antibodies for immuno-fluorescence, goat
anti-mouse Cy3- (AP124C) or Cy2-conjugated (AP124J),
goat anti-rabbit Cy2-conjugated (AP132J), polyvinylidene
difluoride membranes (PVDF; IPVH00010) and
LuminataTM Forte Western HRP Substrate-enhanced
chemiluminiscence reagent (ECL; WBLUF0500) were
from Millipore (Milan, Italy). Protease (P8340) and
phosphatase (P2850) inhibitor cocktails, Hoechst
33258 fluorescent stain (861405) and all the other
chemicals were high grade from Sigma-Aldrich (Milan,
Italy).
Isolation of CLM
Peripheral venous blood was collected using EDTA pre-
coated vials and immediately processed for CLM isola-
tion as previously described [34]. Harvested cells were
suspended in phosphate buffer saline (PBS) pH 7.2–7.4,
counted manually, evaluated for vitality that, using the
trypan blue exclusion test, was close to 95%, and
finally divided into two parts. One was used for WB
assay and the other for IF assay.
Table 1. Demographic data of the neurologically unaffected sub-
jects recruited
Case Sex Age (years)
Ctrl 1 M 33
Ctrl 2 F 57
Ctrl 3 M 65
Ctrl 4 M 48
Ctrl 5 M 76
Ctrl 6 F 61
Ctrl 7 F 53
Ctrl 8 F 64
Ctrl 9 F 66
Ctrl 10 M 58
Mean 58
SD 10
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Subcellular fractionation and western immunoblot
analysis
According to the previously described procedures [34],
the CLM aliquot set for WB assay was divided into two
parts: one was processed to obtain whole cell lysates
and the other to obtain a cytoplasmic and a nuclear
fraction. The latter was performed using ProteoJet Cyto-
plasmic and Nuclear Protein Extraction kit according to
the manufacturer instructions, supplemented with pro-
tease (1% v/v) and phosphatase (2% v/v) inhibitor
cocktails. All preparations were evaluated for protein
amount using the RC-DC protein assay kit, frozen and
stored at 70°C. Frozen samples were then subjected
to SDS-PAGE, and resolved proteins were electro-blotted
onto PVDF membranes, as previously described [34]. Of
note, the protein amount required for the visualization
of TDP-43-immunoreactive band in the cytoplasmic
compartment was at least threefold that required for
the nuclear compartment. Membranes were blocked
with 2% bovine serum albumin (BSA) in Tris-buffered
saline added with 0.02% (v/v) Tween 20 (TBST buffer)
and then exposed at 4°C to the TDP-43 antibody
diluted (1:2000) in 2% BSA in TBST buffer. Probed
blots were then incubated at 4°C with HRP-conjugated
secondary antibodies in TBST buffer, washed and then
incubated with ECL reagent. Immunostained bands
were visualized, using Chemi-Box CCD gel imaging










ALS 1 M 64 14 Spinal No sALS –
ALS 2 M 47 8 Spinal No sALS –
ALS 3 M 66 28 Spinal No sALS –
ALS 4 M 68 38 Spinal No sALS –
ALS 5 M 70 15 Bulbar Yes sALS –
ALS 6 M 66 10 Bulbar No sALS TDP-43 A382T
ALS 7 F 60 29 Spinal No fALS TDP-43 A382T
ALS 8 M 54 19 Spinal No sALS TDP-43 A382T
ALS 9 M 49 48 Bulbar Yes fALS TDP-43 A382T†
ALS 10‡ M 50 120 Spinal No? fALS VCP R191Q
ALS 11§ M 37 61, 76¶ Spinal No fALS VCP R191Q
ALS 12 F 48 32 Spinal Yes fALS FUS R514S
ALS 13 M 40 12 Spinal No fALS FUS R521G
ALS 14** M 27 70 Spinal No fALS SOD1 L84F
ALS 15 F 58 13 Spinal No sALS SOD1 D109Y
ALS 16 F 56 61, 67¶, 98†† Spinal No sALS SOD1 D109Y
ALS 17 M 49 161 Spinal No sALS SOD1 T137A
ALS 18 M 52 103 Spinal No fALS SOD1 I113F
ALS 19 M 38 52 Spinal No fALS SOD1 G93D
ALS 20 M 54 74‡‡ Spinal Yes sALS C9ORF72
ALS 21 M 50 14 Bulbar Yes sALS C9ORF72
ALS 22 F 36 12 Spinal No fALS C9ORF72
ALS 23 M 56 18 Bulbar No sALS C9ORF72
ALS 24 F 57 30 Bulbar No fALS Unknown§§
ALS, amyotrophic lateral sclerosis; fALS, familial ALS; sALS, sporadic ALS; FUS, fused in sarcoma/translocated in liposarcoma; SOD1, Cu/
Zn superoxide dismutase 1; TDP-43, transactive response DNA-binding protein 43; VCP, valosin-containing protein; C9ORF72, chromo-
some 9 open reading frame 72.
*At the time at which the blood sample was taken.
†Homozygous for the mutation. Further clinical data are reported in Borghero et al. [38].
‡III:12 member of the genealogical tree ITALS#1 reported in Johnson et al. [35].
§IV:1 member of the genealogical tree ITALS#1 reported in Johnson et al. [35].
¶Disease duration when the second blood sample was taken.
**This patient was recruited for the first time 62 months before and was reported as case S1 in De Marco et al. [34].
††Disease duration when the third blood sample was taken.
‡‡This patient was recruited for the first time about 4 years before and was reported as case ALS #15 in De Marco et al. [34]. At that
time this case was considered without documented gene mutations.
§§Negative for SOD1, TARDBP, FUS and C9ORF72 mutations.
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system and Genesnap image acquisition software (Syn-
gene, Cambridge, UK). Membranes were re-probed with
antibodies against b-tubulin or lamin B1 to confirm
equal protein loading of the cytoplasmic and nuclear
fractions, respectively. The relative intensity of each
protein band was quantified using GeneTools image
analysis software (Syngene, UK).
In the previous study [34], mean values of
immunoreactive TDP-43 in the cytoplasm and nucleus
were evaluated separately for each group and com-
pared. In this study as the case series was small, we
expressed TDP-43 immunoreactive distribution as a
ratio between normalized nuclear to cytoplasmic
amounts for each case. To unify the interpretation of
observations presently and previously acquired, the
results referred to the previous study were here revised
in terms of nuclear/cytoplasmic ratio (Table 3).
Immunocytofluorescence assay
CLM were fixed in 4% (w/v) paraformaldehyde,
washed with PBS, permeabilized with PBS supple-
mented with 0.1% Triton X-100 (buffer A), blocked at
room temperature in 2% BSA in buffer A and finally
incubated overnight at 4°C with TDP-43 antibody
(1:250 in buffer A) and in some cases co-stained with
ubiquitin antibody (1:250 in buffer A). Cells were
then rinsed with buffer A and incubated at room tem-
perature, in the dark, with secondary antibodies
(1:1000 in buffer A). For nuclear staining, cells were
exposed to Hoechst solution (1:2000 in PBS) at room
temperature in the dark. Fluorescent images were
acquired with inverted microscope Leica DMI 4000 B
(Heidelberg, Germany) and with confocal microscope
Leica TCS SP5 at defined kex.
Characterization of CLM population
Identification of the cellular species in CLM population
was achieved as follows: (i) an aliquot of CLM was
labelled with an antibody that binds the antigen CD45
(leucocyte common antigen), a membrane glycoprotein
featuring hematopoietic cell lines; (ii) an additional
aliquot was treated with MACS Cell separation kit,
according to the manufacturer’s instructions. This
procedure allowed collection of both CD14+ (monocytes/
macrophages) and CD14 (lymphocytes) cells.
Table 3. Subcellular distribution of TDP-43 in CLM, as well as in lymphocytes and monocytes separately, evaluated with WB and/or
immunocytofluorescence (IF) analysis
Controls Nucleus* Cytoplasm* Ratio* Lymphocytes† Monocytes‡
Ctrl #1 1.1 0.7 1.6 n/a n/a
Ctrl #2 1.07 0.68 1.6 n/a n/a
Ctrl #3 0.91 1.3 0.71 n/a n/a
Ctrl #4 0.94 1.2 0.81 n/a n/a
Ctrl #5 1.0 1.0 1.0 n/a n/a
Ctrl #6 0.88 1.4 0.63 n/a n/a
Ctrl #7 1.2 0.80 1.4 n/a n/a
Ctrl #8 1.0 0.82 1.2 n/a n/a
Ctrl #9 1.1 1.0 1.1 n/a n/a
Ctrl #10 1.1 0.99 1.1 n/a n/a
Ctrl #11 0.89 1.3 0.68 n/a n/a
Ctrl #12 1.0 0.89 1.2 n/a n/a
Ctrl #13 0.98 1.1 0.89 n/a n/a
Ctrl 1 0.98 1.0 0.98  2.9
Ctrl 2 1.1 0.83 1.3  2.9
Ctrl 3 1.2 0.75 1.6  4.5
Ctrl 4 0.75 0.95 0.79  3.0
Ctrl 5 1.1 0.98 1.1  3.6
Ctrl 6 0.40 0.85 0.47 + 2.1
Ctrl 7 1.1 1.1 1.0  3.6
Ctrl 8 1.8 0.92 2.0  4.0
Ctrl 9 0.90 1.1 0.82  3.4
Ctrl 10 n/a n/a n/a  3.3
Mean 1.1 Mean 3.3
SD 0.37 SD 0.67
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No mutations Nucleus Cytoplasm Ratio Lymphocytes Monocytes
ALS #5 1.1 0.87 1.3 n/a n/a
ALS #6 0.61 1.9 0.32 n/a n/a
ALS #7 0.95 1.0 0.92 n/a n/a
ALS #8 0.80 1.8 0.44 n/a n/a
ALS #9 0.82 1.8 0.47 n/a n/a
ALS #10 0.66 1.9 0.34 n/a n/a
ALS #11 0.89 1.4 0.63 n/a n/a
ALS #12 0.81 1.7 0.47 n/a n/a
ALS #13 0.84 1.3 0.64 n/a n/a
ALS #14 0.58 2.0 0.30 n/a n/a
ALS #16 0.71 1.8 0.39 n/a n/a
ALS 1 0.70 1.6 0.44 + 2.1
ALS 2 0.85 0.87 0.98  3.0
ALS 3 0.74 1.8 0.41 + 0.80
ALS 4 1.0 0.90 1.2  4.3
ALS 5 1.2 1.0 1.2  2.4
Mean 0.65 Mean 2.5
SD 0.35 SD 1.3
TARDBP+ Nucleus Cytoplasm Ratio Lymphocytes Monocytes
ALS #1 0.77 1.9 0.42 n/a n/a
ALS #2 0.69 1.8 0.38 n/a n/a
ALS #3 0.33 3.8 0.09 n/a n/a
ALS #4 0.18 4.5 0.04 n/a n/a
ALS 6 0.67 1.9 0.35 + 1.5
ALS 7 1.2 1.1 1.1  1.9
ALS 8 n/a n/a n/a + 2.2
ALS 9§ 0.42 1.4 0.29 n/a n/a
P 1¶ 0.58 1.3 0.45 n/a n/a
P 2¶ 0.34 1.7 0.20 n/a n/a
Mean 0.38 Mean 1.9
SD 0.35 SD 0.37
VCP+ Nuclear Cytoplasm Ratio Lymphocytes Monocytes
ALS 10 0.84 1.9 0.44 + 1.8
ALS 11 0.27 1.8 0.15 + 1.2
ALS 11** 0.32 1.6 0.20 + 1.5
Mean†† 0.30 Mean†† 1.5
SD 0.21 SD 0.45
FUS+ Nucleus Cytoplasm Ratio Lymphocytes Monocytes
ALS 12 1.0 0.59 1.7  4.2
ALS 13 1.1 0.72 1.5  3.0
Mean 1.6 Mean 3.6
SD 0.14 SD 0.85
SOD1+ Nucleus Cytoplasm Ratio Lymphocytes Monocytes
ALS 14/ALS S1 0.91 1.2 0.74  3.1
ALS 15 0.70 1.7 0.41 + 1.2
ALS 16 1.0 0.70 1.4  2.9
ALS 16** 1.2 0.80 1.5  3.0
Table 3. (Continued)
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Quantitative analysis The analysis was carried out with
ImageJ 1.48v software (National Institute of Health
Bethesda, MD, USA; http://imagej.nih.gov/ij/) only on
monocytes, since in lymphocytes the cytoplasm usually
covers a minimal part of the entire cell surface, thus
making hard to discriminate the cytoplasmic from the
nuclear compartment.
For each slide, fields (n = 5) were selected and imaged
in three channels corresponding to Hoechst, CD45 and
TDP-43 staining. For the analysis, images were first
converted to grayscale. Hoechst staining was used to
identify the nuclear cell region of interest, and CD45
staining to identify the whole cell surface. Nuclear and
cytoplasmic TDP-43 staining intensities were quantified
after background correction. In monocytes of each sub-
ject, the nuclear/cytoplasmic TDP-43 ratio derives from
the mean value of the ratio between the TDP-43 inten-
sity measured in the nucleus and that measured in the
cytoplasm in at least 10 cells. The mean nuclear/cyto-
plasmic TDP-43 ratio of each group and the relative
standard deviation were also reported (Table 3).
Statistical analysis
Data were analysed with the IBM software Statistical
Package for Statistical Science (SPSS) version 22
Table 3. (Continued)
No mutations Nucleus Cytoplasm Ratio Lymphocytes Monocytes
ALS 16‡‡ n/a n/a n/a  2.9
ALS 17 n/a n/a n/a + 1.8
ALS 18 n/a n/a n/a + 1.9
ALS 19 n/a n/a n/a  3.8
Mean†† 0.85 Mean†† 2.5
SD 0.50 SD 1.0
C9ORF72+ Nucleus Cytoplasm Ratio Lymphocytes Monocytes
ALS 20/ALS #15 1.1 0.98 1.1 n/a n/a
ALS 20** 0.90 1.3 0.69 §§ 2.0
ALS 21 0.53 1.5 0.35 + 1.2
ALS 22 0.86 0.90 0.96  1.4
ALS 23 0.36 0.58 0.62 §§ 1.3
Mean†† 0.76 Mean 1.5
SD 0.34 SD 0.36
Unknown gene Nucleus Cytoplasm Ratio Lymphocytes Monocytes
ALS 24 n/a n/a n/a  3.2
Cases and results reported in De Marco et al. [34] are shown in italics. Each value results from three independent experiments.
n/a, data not available; ALS, amyotrophic lateral sclerosis; CLM, circulating lymphomonocytes; FUS, fused in sarcoma/translocated in
liposarcoma; SOD1, Cu/Zn superoxide dismutase 1; TDP-43, transactive response DNA-binding protein 43; VCP, valosin-containing pro-
tein; WB, western immunoblot; C9ORF72, chromosome 9 open reading frame 72.
*Values refer to the TDP-43 immunostaining intensity measured in CLM with WB analysis, normalized respect to lamin B1 (nucleus) and
b-tubulin (cytoplasm) and expressed as a nuclear/cytoplasmic ratio.
†Distribution of TDP-43 in lymphocytes detected with IF assay: () TDP-43 uniformly distributed on the entire cell surface of most cells;
(+) TDP-43 distributed in the perinuclear area of most cells.
‡Values refer to the TDP-43 immunostaining intensity measured with IF assay in the nucleus and cytoplasm of at least 10 monocytes
and expressed as a nuclear/cytoplasmic ratio.
§Patient homozygous for the mutation.
¶ALS 9 patient’s relative, who did not show any neurological sign of the disease.
**Case tested for the second time after a defined lapse of time.
††For patients tested more than once, only the values obtained in the first analysis are considered for the calculation of mean and stan-
dard deviation.
‡‡Case tested for the third time after a defined lapse of time.
§§TDP-43 cytoplasmic accumulation was appreciable in many cells, but not in the majority.
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(Armonk, NY, USA). Student’s t-test was used to com-
pare each group of patients carrying the same mutant
gene with the control group or to compare two
groups of patients. One-way ANOVA test with Tukey
correction was used for comparisons among more
than two groups of patients.
Results
Characterization of CLM
IF analysis was performed using the inverted micro-
scope, as well as the confocal microscope. Immunola-
belling with CD45 revealed that CLM population
consisted of leucocytes with an intact plasma mem-
brane in controls as well as in patients. Furthermore,
CD45 and Hoechst staining disclosed that the popula-
tion included two types of cells differing in size as well
as in the nuclear shape (Figure 1a). Treatment of CLM
with MACS Cell separation kit, followed by staining
with Hoechst reagent, revealed that the bigger cells,
usually characterized by a kidney or horseshoe-shaped
nucleus, were monocytes (CD14+ cells) and the smaller
ones were lymphocytes (CD14 cells) (Figure 1b).
Correlation between TDP-43 subcellular localization
and gene mutations
In whole lysates and in nuclear and cytoplasmic frac-
tions of CLM from all individuals, TDP-43 profile
matched, in qualitative terms, that of controls and
patients with mutant TARDBP or without gene muta-
tions previously considered [34]. In detail, full length
TDP-43 (~45 kDa) was a feature of whole lysates and
nucleus, whereas the shortly truncated form at
~42 kDa only of cytoplasm. The TDP-43 immunoreac-
tive band at ~38 kDa was detected in whole lysates and
in the two subcellular compartments in all cases
Figure 1. Types of cells included in circulating lymphomonocytes (CLM) population identified by immunofluorescence microscopy. (a)
CLM of a control and a patient tested with an antibody directed to the CD45 antigen, selective for all white blood cells (leucocytes). (b)
MACS Cell separation kit allowed to identify, in CLM population, monocytes (CD14+) and lymphocytes (CD14). The two isolated
clones in a neurologically unaffected control were visualized following staining with Hoechst reagent. Green: CD45 antibody; blue:
Hoechst reagent for nuclear staining. All images were taken at 1009 magnification, and the scale bars represent 10 lm.
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(Figure 2a). As previously observed, in quantitative
terms, in CLM whole lysates TDP-43 did not differ signif-
icantly among the individuals considered (Figure 2a).
The analysis of TDP-43 subcellular localization with
IF assay was performed in quantitative terms in mono-
cytes and only in qualitative terms in lymphocytes (see
Methods). In the latter, TDP-43 was considered not to
accumulate in the cytoplasm, when protein immunola-
belling was uniformly distributed on the entire cell sur-
face of most cells, and instead to accumulate when the
immunolabelling was prominently localized in the per-
inuclear area of most cells (Figures 3a, S1).
Controls, TARDBP+ individuals and patients without
documented gene mutations
The mean nuclear/cytoplasmic TDP-43 ratio, obtained
with WB assay (see Methods), in the TARDBP+ group
was lower than that of controls (P < 0.01) (Figure 2b,
Table 2). Thus, the results of the previous and present
study confirmed TDP-43 accumulation in the
cytoplasm of CLM of TARDBP+ patients. For each
group, TDP-43 was considered to accumulate in the
cytoplasm of CLM if the ratio mean value was
significantly lower (at least P < 0.05) with respect to
that of controls.
Figure 2. (a) Transactive response DNA-binding protein 43 (TDP-43) profile in western immunoblots of whole lysates and nuclear and
cytoplasmic fractions from circulating lymphomonocytes (CLM) of patients with various mutant genes linked to amyotrophic lateral
sclerosis (ALS); lamin B1 and b-tubulin were used as a loading control for the nuclear and cytoplasmic fractions, respectively.
Arrowhead: 38 kDa protein band. (b) The scatter plot refers to the ratio between the nuclear and cytoplasmic TDP-43 amount in CLM of
all individuals here examined, revealed with western immunoblot assay and normalized with lamin B1 and b-tubulin respectively
(Table 3). Each point is the result of at least three independent experiments. The mean values, as well as the standard deviations, are
reported for each group considered. Empty circles represent the nuclear/cytoplasmic TDP-43 ratio of the subjects analysed in the previous
study [34]. The group of TARDBP+ includes a case homozygous for the mutation (diamond) and its neurologically unaffected relatives
heterozygous for the mutation (square). Arrows: variation in the ratio in patients reconsidered after a definite lapse of time. *P < 0.05 vs.
control group; **P < 0.01 vs. control group.
© 2016 British Neuropathological Society
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The ratios of the two neurologically unaffected rela-
tives heterozygous for the mutation (P1, P2) were both
below the ratios of 90% of controls; in addition, in one,
the ratio was below, whereas in the other it was above,
the ratio of the homozygous ALS-affected relative (Fig-
ure 2b, Table 3).
IF analysis revealed that the mean nuclear/cytoplas-
mic ratio value in monocytes of the control group was
3.3 (range = 2.1–4.5). Thus, in monocytes the average
amount of TDP-43 in the nucleus is about threefold
that in the cytoplasm. Only the subject with the lowest
ratio in monocytes showed TDP-43 cytoplasmic accu-
mulation in lymphocytes.
In the TARDBP+ group, the mean nuclear/cytoplas-
mic TDP-43 ratio in monocytes was lower than that of
controls (P < 0.01). Furthermore, the ratios of all the
TARDBP+ patients were below those in 90% of controls
(Figure 3, Table 3). Thus, TDP-43 cytoplasmic accu-
mulation in monocytes was considered to be a feature
of all patients belonging to this group. In two patients
(ALS 6, ALS 8) TDP-43 cytoplasmic accumulation was
found also in lymphocytes. Instead, in another patient
(ALS 7), TDP-43 cytoplasmic accumulation was not
disclosed in lymphocytes nor in CLM (in the latter, the
nuclear/cytoplasmic ratio obtained with WB analysis
was close to the mean value of the control group) (Fig-
ures 2b, 3b, Table 3).
WB analysis showed that, in patients without docu-
mented gene mutations, TDP-43 accumulated in the
cytoplasm of CLM (P < 0.01 vs. control group). How-
ever, the TDP-43 ratios of some of these patients
were above those of one-third of controls and even
above the mean value of controls (Figure 2b, Table 3).
Three of these patients were analysed with IF assay. In
one (ALS 5), TDP-43 accumulation was not found in
lymphocytes and instead disclosed in monocytes, since
the nuclear/cytoplasmic TDP-43 ratio was below that
of 90% of controls (Figure 3, Table 3).
VCP+ patients
WB assay disclosed that TDP-43 accumulated in the
cytoplasm of CLM of these patients (P < 0.05 vs. control
group). Accumulation of TDP-43 was disclosed also in
monocytes (IF assay), since the mean ratio in this group
was significantly lower than that of controls (P < 0.01)
and the ratios of the two VCP+ patients were both below
those of 90% of controls. TDP-43 cytoplasmic
accumulation characterized also lymphocytes of these
patients. One (ALS 11) was reprobed 15 months later
and accumulation in both lymphocytes and monocytes
(as well as in CLM) was confirmed (Figure 3, Table 3).
FUS+ patients
In two patients, TDP-43 ratios calculated in CLM (WB
assay) as well as in monocytes (IF assay) were not
significantly different respect to those in the control
group. Furthermore, in both, TDP-43 cytoplasmic
accumulation was not found in lymphocytes (Figure 3,
Table 3).
SOD1+ patients
In these patients, the mean TDP-43 ratio in CLM (WB
assay) was not significantly different respect to that of
controls (Figure 2, Table 3). However, the TDP-43
ratios in monocytes (IF assay) in three patients of this
group (ALS 15, ALS 17, ALS 18) were below those in
90% of controls and thus monocytes of these patients
were considered to accumulate TDP-43 in the
cytoplasm. In these three cases, TDP-43 cytoplasmic
accumulation was revealed also in lymphocytes
(Figures 2, 3, Table 3). Instead, in three other patients
(ALS 14, ALS 16, ALS 19), TDP-43 cytoplasmic
accumulation was not detected in monocytes (the
ratios were not below those found in 90% of controls)
nor in lymphocytes. Cytoplasmic accumulation was not
found when one of these cases (ALS 16) was recruited
7 and 31 months later (Figures 2, 3, Table 3).
Figure 3. (a) Transactive response DNA-binding protein 43 (TDP-43) subcellular localization, detected by fluorescence microscopy, in
circulating lymphomonocytes from neurologically unaffected controls, amyotrophic lateral sclerosis (ALS) patients without documented
gene mutations, ALS patients with mutant TARDBP, valosin-containing protein (VCP), fused in sarcoma/translocated in liposarcoma (FUS), Cu/
Zn superoxide dismutase 1 (SOD1) and chromosome 9 open reading frame 72 (C9ORF72); red: TDP-43 antibody; blue: Hoechst reagent for
nuclear staining. All images were taken at 1009 magnification, and the scale bars represent 10 lm. The images are representative of at
least four sections. (b) The scatter plot refers to the ratio between the nuclear and cytoplasmic intensities of TDP-43 in monocytes of all
individuals here tested with immunocytofluorescence assay. Each point represents the mean nuclear/cytoplasmic TDP-43 ratio calculated
on at least 10 monocytes of each individual (Table 3). The mean values, as well as the standard deviations, are reported for each group
considered. Arrows: variation in the ratio in patients reconsidered after a defined lapse of time. **P < 0.01 vs. control group.
© 2016 British Neuropathological Society
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C9ORF72+ patients
In these patients, the mean TDP-43 ratio in CLM (WB
assay) was not significantly different with respect to
that of controls (Figure 2, Table 3). By contrast, IF
analysis disclosed TDP-43 cytoplasmic accumulation in
monocytes of all patients of this group (P < 0.01 vs.
controls and all the ratio values were below those
disclosed in 90% of controls; Figure 3, Table 3). In one
patient (ALS 21), in whom the ratio in CLM (WB
assay) was below that of all controls, TDP-43
cytoplasmic accumulation was detected also in
lymphocytes. Instead, in one patient (ALS 22), TDP-43
cytoplasmic accumulation was not found in
lymphocytes. In two patients (ALS 23, ALS 20),
distribution was judged to be intermediate because
TDP-43 accumulation was appreciable in many cells,
but not in the majority (Table 3). One of these patients
(ALS 20) had been tested previously [34] and included
in the group of patients without gene mutations
(reported as ALS #15) because C9ORF72 mutations
had not yet been linked to ALS. At that time, the
nuclear/cytoplasmic TDP-43 ratio of CLM (WB assay)
coincided with the mean ratio of the control group.
However, when this patient was retested in this study
(52 months after the first evaluation), the ratio was
below that of 87% of controls (Figure 2b, Table 3).
fALS patient with unknown gene mutation
In a fALS patient with unknown gene mutation (ALS
24), TDP-43 accumulation was detected neither in
lymphocytes nor in monocytes, since the TDP-43 ratio
(IF assay) was close to the mean value of controls
(Figure 3b, Table 3).
Correlation between TDP-43 subcellular localization
in CLM and clinical as well as demographic
parameters
In ALS patients, no significant difference was found
when the nuclear/cytoplasmic TDP-43 ratio was corre-
lated with gender, familiarity for the disease, age at dis-
ease onset, age at blood sample collection or disease
duration. The ratio was significantly lower (P < 0.05)
in patients with bulbar respect to spinal disease onset
(Figure 4).
Evaluation of ubiquitin immunoreactivity
In CLM of controls and patients ubiquitin immunoreac-
tivity was diffusely distributed. Furthermore, double-
labelling of TDP-43 and ubiquitin did not disclose ubiq-
uitin-positive aggregates, even in those cells in which
cytoplasmic accumulation of TDP-43 was manifest
(Figure 5).
Discussion
Sequestration of TDP-43 inside ubiquitin-immunoreac-
tive inclusions in motor neurons is the hallmark of most
ALS cases [22–24]. This feature, detectable only at
autopsy, is preceded by accumulation of TDP-43 in the
cytoplasm along with depletion in the nucleus [4,26–
28,30]. Previously [34], we reported TDP-43 accumula-
tion in the cytoplasm of CLM of ALS patients with
mutant TARDBP and of about half of patients without a
documented genetic background for the disease. Here,
we evaluate if, in ALS patients with other disease-linked
mutant genes besides TARDBP, TDP-43 subcellular
localization in CLM reproduces that found in motor neu-
rons of corresponding cases. In addition, we analyse the
TDP-43 profile in lymphocytes and monocytes sepa-
rately, the two cell types constituting CLM.
In motor neurons of ALS-affected cases, mutant
TARDBP is considered to be a determinant of TDP-43
mislocalization [4,28,30–33]. Our previous and present
observations show that, in ALS-affected patients, muta-
tions of this gene are associated with TDP-43 cytoplas-
mic accumulation also in CLM, as well as in
lymphocytes and monocytes. Interestingly, in one of
these patients the accumulation was restricted to
monocytes. Cytoplasmic accumulation of TDP-43 is a
feature also of CLM of subjects carrying mutant
TARDBP, even in the absence of signs of the disease. In
fact, the accumulation in CLM was observed previously
Figure 4. Correlation between transactive response DNA-binding protein 43 (TDP-43) subcellular distribution in circulating
lymphomonocytes and various clinical parameters in amyotrophic lateral sclerosis (ALS)-affected patients. The parameters include:
gender, familiarity for the disease, site of onset, age at blood sample collection and disease duration at blood sample collection. For age at
blood sample collection and disease duration, the correlation is reported by dividing patients according to age or disease duration ranges
as well as in terms of linear regression between time and TDP-43 ratio. *P < 0.05 vs. the other group.
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in one [34], and here in two neurologically unaffected
individuals carrying the familial TARDBP mutation.
The accumulation was not more severe in a relative of
the latter two individuals, who was ALS-affected and
homozygous for the mutation. It is conceivable that the
accumulation, besides being unrelated to the presence
of perceptible signs of disease, is also unrelated to the
amount of mutated protein in the cell.
Mutations of VCP are associated with TDP-43 alter-
ations in post mortem nervous tissue as well as in biop-
sied muscle of various neurodegenerative diseases, in
murine motor neurons and in cell lineages [35,40–48].
In agreement with these observations, in the ALS
patients with mutant VCP tested in this study, TDP-43
was revealed to accumulate in cytoplasm of CLM, as
well as in that of lymphocytes and monocytes evalu-
ated separately; this feature was confirmed in one of
these patients when re-probed about 1 year later.
In motor neurons of ALS cases with mutant FUS the
encoded protein is sequestered inside cytoplasmic ubiq-
uitinylated inclusions but TDP-43 is not a component
of these inclusions [4,5,49–53]. Furthermore, the pro-
tein complexes that control nuclear/cytoplasmic traf-
ficking of FUS differ with respect to those controlling
TDP-43 [54,55]. Accordingly, in patients with mutant
FUS enrolled in this study TDP-43 did not accumulate
in the cytoplasm of lymphocytes or monocytes.
Alterations of TDP-43 are described to be absent in
post mortem motor neurons of ALS cases with SOD1
mutations [4,23,53,56]. However, some exceptions
have been disclosed [57–60] and evidence supports the
existence of a link between TDP-43 and SOD1 in the
pathogenesis of ALS [61–63]. Here, in the group of
patients carrying SOD1 mutations, TDP-43 subcellular
localization in CLM was heterogeneous. In fact, in some
cases TDP-43 cytoplasmic accumulation was observed
in both monocytes and lymphocytes whereas in others
neither in monocytes nor in lymphocytes. At present,
the absence of a comparison between CLM and motor
neurons from the same subject makes it impossible to
establish whether there is a correspondence between
TDP-43 localization in CLM and motor neurons in this
Figure 5. Double immunolabelling of circulating lymphomonocytes (CLM) with transactive response DNA-binding protein 43 (TDP-43)
and ubiquitin in CLM from a neurologically unaffected control and of two amyotrophic lateral sclerosis (ALS) patients. Ctrl 1:
neurologically unaffected control; ALS 3: patient without gene mutations; ALS 6: patient with mutant TARDBP. Red: TDP-43 antibody;
green: ubiquitin antibody. All images were taken at 1009 magnification, and the scale bars represent 10 lm. The images are
representative of at least four sections.
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category of patients. TDP-43 alterations have been dis-
covered in nervous tissue of cases with SOD1 muta-
tions involving Cys111, Ile112 or Ile113 [57–59]. Of
note, TDP-43 cytoplasmic accumulation was detected
in CLM of one patient carrying a SOD1 mutation
involving Ile113.
A hexanucleotide repeat within a non-coding region
of the C9ORF72 is the most common mutation found
in ALS [2,37,64,65]. Cytoplasmic ubiquitinylated inclu-
sions immunoreactive for TDP-43 are a feature of post
mortem motor neurons of ALS cases with mutant
C9ORF72 [37,66–68]. However, neuronal aggregates
negative for TDP-43, but enriched in other proteins
(such as p62), are considered pathognomonic for this
group of patients [36,69–71]. Furthermore, TDP-43
dysfunctions may or may not characterize cell lineages
with mutant C9ORF72 [72,73]. Herein, of the mutant
C9ORF72 patients recruited, cytoplasmic accumulation
of TDP-43 was manifest in monocytes in all and also
in lymphocytes only in one. In one of the patients, the
nuclear/cytoplasmic TDP-43 ratio had decreased when
re-tested 4 years after the first evaluation (when the
ratio was in the control range) [34]. Therefore, in this
lapse of time, TDP-43 cytoplasmic accumulation must
have involved ever more monocytes and possibly lym-
phocytes (many lymphocytes, although not most,
showed perinuclear TDP-43 accumulation, see Results).
This outcome suggests that, in CLM of patients with
mutant C9ORF72, TDP-43 cytoplasmic accumulation
progresses over time. In this respect, there is evidence
that mutant C9ORF72 affects TDP-43 indirectly and
evolves over time in motor neurons [65,71]. Possibly,
the follow up of the disease in these patients benefits
from the evaluation of TDP-43 subcellular distribution
in monocytes and lymphocytes.
In a fALS patient with unknown genetic background,
TDP-43 cytoplasmic accumulation was not observed
either in lymphocytes or in monocytes. While awaiting
the genetic identification of this case, this outcome sug-
gests that the mutated gene is not associated with
TDP-43 proteinopathy (i.e. FUS-like) or concurs to its
development over time (as suspected for mutant
C9ORF72).
No correlation was found between TDP-43 subcellular
distribution and gender, familial disease, age at disease
onset, age at blood sample collection and disease dura-
tion. Instead, significantly greater cytoplasmic accumu-
lation was found in CLM of patients with bulbar rather
than spinal site of disease onset. However, this result
needs to be confirmed on a larger case series.
This study disclosed that in all cases in which WB
assay reveals cytoplasmic accumulation of TDP-43 in
CLM, IF assay detects this accumulation in both lym-
phocytes and monocytes. Instead, in cases in which
WB analysis did not reveal TDP-43 cytoplasmic accu-
mulation in CLM, IF assay disclosed that there was not
always concordance between lymphocytes and mono-
cytes. In fact, in one patient with mutant TARDBP and
three patients with mutant C9ORF72 (see above) as
well as in one patient without documented gene muta-
tions, TDP-43 cytoplasmic accumulation was detected
in monocytes but not in lymphocytes. These patients
can all be expected to have, or to develop over time,
TDP-43 mislocalization in motor neurons. Instead,
accumulation in lymphocytes and not in monocytes
was never observed. Thus, in all those cases in which
cytoplasmic accumulation of TDP-43 was detected with
WB assay, the alteration must have characterized both
cell types. TDP-43 cytoplasmic accumulation is not
detected with WB assay when it is a feature of only
monocytes, likely because monocytes constitute only
10–20% of CLM population and WB assay does not dis-
criminate between lymphocytes and monocytes. Thus,
from the clinical point of view, the analysis of TDP-43
subcellular localization in monocytes is more sensitive
than that in CLM in identifying patients who have mis-
localized TDP-43 in their motor neurons. We do not
know why lymphocytes sometimes do not manifest the
TDP-43 alteration featuring motor neurons when
instead monocytes do. It would not appear to be a
question of severity of disease since TDP-43 cytoplas-
mic accumulation was disclosed in CLM (i.e. both lym-
phocytes and monocytes) of neurologically unaffected
individuals carrying mutant TARDBP. However, we
can conclude that monocytes, more reliably than lym-
phocytes, reflect the molecular background that in
motor neurons is associated with their degeneration. In
this regard, ALS is a multisystem disease in which
monocytes are described to play a role in the pathogen-
esis [9]. In fact, recruitment of inflammatory mono-
cytes in the CNS appears to be related to disease
progression [74] and activated monocytes/macrophages
have been found in blood samples from sALS patients
[75]. Furthermore, activation of microglia, a cell type
which shares with monocytes a common embryonic
hematopoietic precursor [76,77] and in particular
© 2016 British Neuropathological Society
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conditions can even derive from monocytes [78], is
associated with TDP-43 proteinopathy in the brain of
ALS cases [10].
In motor neurons of ALS patients, sequestration of
TDP-43 inside cytoplasmic ubiquitinylated inclusions is
associated with cell degeneration [22–24,79]. Further-
more, accumulation of TDP-43 in the cytoplasm pre-
cedes the formation of ubiquitinylated inclusions [27]
and is considered an early step in ALS pathogenesis
[4,27–29]. Here, accumulation of TDP-43 in the cyto-
plasm of CLM is not associated with cell degeneration
since plasma membrane integrity and nuclear shape are
preserved, and occurs in the absence of ubiquitinylated
inclusions. Furthermore, cytoplasmic accumulation of
TDP-43 in CLM is rarely associated with complete
nuclear depletion, as instead occurs in motor neurons
[25,26,32]. Additionally, TDP-43 fragments character-
izing inclusions in motor neurons [24,80–82] have not
been detected in CLM of ALS patients, and fragments of
the size seen in CLM (~42 kDa) have not been observed
in motor neurons [34]. Possibly, the mechanisms
underlying TDP-43 fragmentation and ubiquitination in
motor neurons differ with respect to those in CLM.
Alternatively, CLM, which have a much shorter life
span than motor neurons, might not live long enough
for ubiquitin-immunoreactive inclusions to develop.
In conclusion, in patients with various ALS-linked
mutant genes, there appears to be a close parallel
between TDP-43 distribution in CLM and that in motor
neurons, whether altered or not. Interestingly, mislo-
calization of TDP-43 occurs in motor neurons, in CLM
and even more in monocytes, irrespective of whether
the protein is wild type or not. This suggests that TDP-
43 localization in monocytes and motor neurons is reg-
ulated by similar mechanisms and that stimuli impair-
ing TDP-43 localization in motor neurons also do so in
monocytes. In this view, monocytes may be used to
support the diagnosis of ALS, as well as to identify sub-
jects at risk of disease. Additionally, monocytes may be
exploited to investigate the mechanisms involved in the
initial stages of ALS, in the hope to find treatments that
prevent, or at least delay, motor neuron death.
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Figure S1. Transactive response DNA-binding protein
43 (TDP-43) subcellular localization, detected by
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confocal microscopy, in circulating lymphomonocytes
(CLM) from a neurologically unaffected control and
three amyotrophic lateral sclerosis (ALS) patients, one
with TARDBP mutation and the other two without
documented gene mutations.
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